Caffeic amide derivatives inhibit allergen-induced bone marrow-derived dendritic cell maturation

Yueh Lun Lee, Ling Heng Hsu, Yueh Hsiung Kuo, Chen Chen Lee

Research output: Contribution to journalArticle

Abstract

Background: Caffeic amides are derivatives of caffeic acid, which have antioxidant and anti-inflammatory properties, and high in vivo stability. The therapeutic effect of caffeic amides on allergic diseases, and especially on the maturation of bone marrow-derived dendritic cells (BM-DCs), remains unclear. In this study, we investigated the therapeutic potential of caffeic amides on allergic diseases by evaluating the maturation of DCs and evaluated their potential in inducing the differentiation of T H 2 cells. Methods: BM-DCs isolated from BALB/c mice were treated with different caffeic amide derivatives for 48 h and the expression of surface markers was analyzed by flow cytometry. The differentiation of CD4 + T cells was detected by the 5-bromo-2-deoxyuridine (BrdU) incorporation assay and cytokine production was analyzed by ELISA. Results: Our results showed that among the six caffeic amides tested herein, only 36 M significantly inhibited the antigen-induced maturation of DCs associated with the expression of CD80, CD86, and major histocompatibility complex II (VC ovalbumin (OVA)+ thymic stromal lymphopoietin (TSLP) vs. 36 M OVA + TSLP). Additionally, the isolation and co-culture of antigen-specific CD4 + T cells with 36 M-treated BM-DCs suppressed the antigen-specific differentiation of T H 2 cells. Conclusion: Among the six caffeic amides tested herein, 36 M (N-octyl caffeamide) might possess therapeutic potential for allergic diseases.

Original languageEnglish
Pages (from-to)194-200
Number of pages7
JournalPharmacological Reports
Volume71
Issue number2
DOIs
Publication statusPublished - Apr 1 2019

Fingerprint

Amides
Allergens
Dendritic Cells
Bone Marrow
Ovalbumin
T-Lymphocytes
CD4 Antigens
Differentiation Antigens
Therapeutic Uses
Bromodeoxyuridine
Coculture Techniques
Major Histocompatibility Complex
Flow Cytometry
Anti-Inflammatory Agents
Antioxidants
Enzyme-Linked Immunosorbent Assay
Cytokines
Antigens
Therapeutics
thymic stromal lymphopoietin

Keywords

  • Allergy
  • Caffeic amide
  • Dendritic cell
  • T cell

ASJC Scopus subject areas

  • Pharmacology

Cite this

Caffeic amide derivatives inhibit allergen-induced bone marrow-derived dendritic cell maturation. / Lee, Yueh Lun; Hsu, Ling Heng; Kuo, Yueh Hsiung; Lee, Chen Chen.

In: Pharmacological Reports, Vol. 71, No. 2, 01.04.2019, p. 194-200.

Research output: Contribution to journalArticle

Lee, Yueh Lun ; Hsu, Ling Heng ; Kuo, Yueh Hsiung ; Lee, Chen Chen. / Caffeic amide derivatives inhibit allergen-induced bone marrow-derived dendritic cell maturation. In: Pharmacological Reports. 2019 ; Vol. 71, No. 2. pp. 194-200.
@article{0ca2108563cc43fa8a0e4df2b07aedab,
title = "Caffeic amide derivatives inhibit allergen-induced bone marrow-derived dendritic cell maturation",
abstract = "Background: Caffeic amides are derivatives of caffeic acid, which have antioxidant and anti-inflammatory properties, and high in vivo stability. The therapeutic effect of caffeic amides on allergic diseases, and especially on the maturation of bone marrow-derived dendritic cells (BM-DCs), remains unclear. In this study, we investigated the therapeutic potential of caffeic amides on allergic diseases by evaluating the maturation of DCs and evaluated their potential in inducing the differentiation of T H 2 cells. Methods: BM-DCs isolated from BALB/c mice were treated with different caffeic amide derivatives for 48 h and the expression of surface markers was analyzed by flow cytometry. The differentiation of CD4 + T cells was detected by the 5-bromo-2-deoxyuridine (BrdU) incorporation assay and cytokine production was analyzed by ELISA. Results: Our results showed that among the six caffeic amides tested herein, only 36 M significantly inhibited the antigen-induced maturation of DCs associated with the expression of CD80, CD86, and major histocompatibility complex II (VC ovalbumin (OVA)+ thymic stromal lymphopoietin (TSLP) vs. 36 M OVA + TSLP). Additionally, the isolation and co-culture of antigen-specific CD4 + T cells with 36 M-treated BM-DCs suppressed the antigen-specific differentiation of T H 2 cells. Conclusion: Among the six caffeic amides tested herein, 36 M (N-octyl caffeamide) might possess therapeutic potential for allergic diseases.",
keywords = "Allergy, Caffeic amide, Dendritic cell, T cell",
author = "Lee, {Yueh Lun} and Hsu, {Ling Heng} and Kuo, {Yueh Hsiung} and Lee, {Chen Chen}",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.pharep.2018.10.014",
language = "English",
volume = "71",
pages = "194--200",
journal = "Pharmacological Reports",
issn = "1734-1140",
publisher = "Polish Academy of Sciences Publishing House",
number = "2",

}

TY - JOUR

T1 - Caffeic amide derivatives inhibit allergen-induced bone marrow-derived dendritic cell maturation

AU - Lee, Yueh Lun

AU - Hsu, Ling Heng

AU - Kuo, Yueh Hsiung

AU - Lee, Chen Chen

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Background: Caffeic amides are derivatives of caffeic acid, which have antioxidant and anti-inflammatory properties, and high in vivo stability. The therapeutic effect of caffeic amides on allergic diseases, and especially on the maturation of bone marrow-derived dendritic cells (BM-DCs), remains unclear. In this study, we investigated the therapeutic potential of caffeic amides on allergic diseases by evaluating the maturation of DCs and evaluated their potential in inducing the differentiation of T H 2 cells. Methods: BM-DCs isolated from BALB/c mice were treated with different caffeic amide derivatives for 48 h and the expression of surface markers was analyzed by flow cytometry. The differentiation of CD4 + T cells was detected by the 5-bromo-2-deoxyuridine (BrdU) incorporation assay and cytokine production was analyzed by ELISA. Results: Our results showed that among the six caffeic amides tested herein, only 36 M significantly inhibited the antigen-induced maturation of DCs associated with the expression of CD80, CD86, and major histocompatibility complex II (VC ovalbumin (OVA)+ thymic stromal lymphopoietin (TSLP) vs. 36 M OVA + TSLP). Additionally, the isolation and co-culture of antigen-specific CD4 + T cells with 36 M-treated BM-DCs suppressed the antigen-specific differentiation of T H 2 cells. Conclusion: Among the six caffeic amides tested herein, 36 M (N-octyl caffeamide) might possess therapeutic potential for allergic diseases.

AB - Background: Caffeic amides are derivatives of caffeic acid, which have antioxidant and anti-inflammatory properties, and high in vivo stability. The therapeutic effect of caffeic amides on allergic diseases, and especially on the maturation of bone marrow-derived dendritic cells (BM-DCs), remains unclear. In this study, we investigated the therapeutic potential of caffeic amides on allergic diseases by evaluating the maturation of DCs and evaluated their potential in inducing the differentiation of T H 2 cells. Methods: BM-DCs isolated from BALB/c mice were treated with different caffeic amide derivatives for 48 h and the expression of surface markers was analyzed by flow cytometry. The differentiation of CD4 + T cells was detected by the 5-bromo-2-deoxyuridine (BrdU) incorporation assay and cytokine production was analyzed by ELISA. Results: Our results showed that among the six caffeic amides tested herein, only 36 M significantly inhibited the antigen-induced maturation of DCs associated with the expression of CD80, CD86, and major histocompatibility complex II (VC ovalbumin (OVA)+ thymic stromal lymphopoietin (TSLP) vs. 36 M OVA + TSLP). Additionally, the isolation and co-culture of antigen-specific CD4 + T cells with 36 M-treated BM-DCs suppressed the antigen-specific differentiation of T H 2 cells. Conclusion: Among the six caffeic amides tested herein, 36 M (N-octyl caffeamide) might possess therapeutic potential for allergic diseases.

KW - Allergy

KW - Caffeic amide

KW - Dendritic cell

KW - T cell

UR - http://www.scopus.com/inward/record.url?scp=85061658034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061658034&partnerID=8YFLogxK

U2 - 10.1016/j.pharep.2018.10.014

DO - 10.1016/j.pharep.2018.10.014

M3 - Article

VL - 71

SP - 194

EP - 200

JO - Pharmacological Reports

JF - Pharmacological Reports

SN - 1734-1140

IS - 2

ER -